

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 10, 2009**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Fresenius Kabi Pharmaceuticals Holding, Inc.**

**File No. 1-34172 - CF#22880**

---

Fresenius Kabi Pharmaceuticals Holding, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 14, 2008.

Based on representations by Fresenius Kabi Pharmaceuticals Holding, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.17	through September 10, 2014
Exhibit 10.19	through September 10, 2014
Exhibit 10.21	through September 10, 2015

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Karen J. Garnett  
Assistant Director